Bicycle Therapeutics slides on $125 mln share offering
** Drug developer's shares BCYC.O drop as much as 3% to
$52
** Co commences offering of American Depositary Shares (ADS)
worth $125 mln urn:newsml:reuters.com:*:nBwb0f4p2a
** Each ADS represents one ordinary share, co says
** BCYC plans to use proceeds from offering to fund future
products and research and development
** Goldman Sachs & Co, Morgan Stanley and SVB Leerink are
the underwriters
(Reporting by Niket Nishant in Bengaluru)
((Niket.Nishant@thomsonreuters.com;))
Recent news on Bicycle Therapeutics
See all newsBicycle Therapeutics Q1 revenue drops after partnership terminations
Brief: Bicycle Therapeutics Announces Oral And Poster Presentations At The Aacr Annual Meeting 2026
UK's Bicycle Therapeutics Q4 revenue jumps, proposes 30% workforce reduction
Brief: Bicycle Therapeutics Says Travis Thompson Appointed As CFO, Succeeds Alethia Young
Bicycle Therapeutics Q3 net loss widens as R&D costs rise